Literature DB >> 33301836

Antigen folding improves loading efficiency and antitumor efficacy of PC7A nanoparticle vaccine.

Jonathan Wilhelm1, Manuel Quiñones-Pérez1, Jian Wang1, Xu Wang1, Vijay S Basava1, Jinming Gao2.   

Abstract

Cancer vaccines hold great promise to produce antigen-specific T cell immunity for personalized therapy of cancer. Previously, we reported an ultra-pH-sensitive nanoparticle, PC7A, capable of priming an efficacious immune response without significant systemic toxicity. Despite the early success, the relationship between antigen properties and encapsulation efficiency for downstream immune activation remains poorly understood. In this study, we investigated a small library of melanoma antigens and the effects of several formulation methods on the efficiency of peptide loading inside PC7A nanoparticles. Results show loading efficiency is not highly dependent on the formulation methods, but instead mainly driven by the peptide antigen properties. In particular, we identified a phase transition event, namely the folding of antigenic peptides from random coils to α-helical structure, is important for antigen loading inside PC7A nanoparticles. Mutation of a peptide that abrogates the formation of helical structure resulted in poor loading efficiency. Antitumor efficacy studies in melanoma-bearing mice demonstrate the importance of peptide loading in vaccine-induced antitumor immunity. This study highlights the contribution of phase transition of peptide antigens on vaccine formulation in order to make widespread use of personalized nanoparticle vaccines feasible.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antigen delivery; Cancer vaccine; Peptide encapsulation; Secondary structure; Ultra-pH sensitive micelles

Mesh:

Substances:

Year:  2020        PMID: 33301836      PMCID: PMC7904583          DOI: 10.1016/j.jconrel.2020.11.056

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  42 in total

Review 1.  "Green" atom transfer radical polymerization: from process design to preparation of well-defined environmentally friendly polymeric materials.

Authors:  Nicolay V Tsarevsky; Krzysztof Matyjaszewski
Journal:  Chem Rev       Date:  2007-05-27       Impact factor: 60.622

Review 2.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

3.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 4.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

5.  Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.

Authors:  Lars Hofmann; Andrea Forschner; Carmen Loquai; Simone M Goldinger; Lisa Zimmer; Selma Ugurel; Maria I Schmidgen; Ralf Gutzmer; Jochen S Utikal; Daniela Göppner; Jessica C Hassel; Friedegund Meier; Julia K Tietze; Ioannis Thomas; Carsten Weishaupt; Martin Leverkus; Renate Wahl; Ursula Dietrich; Claus Garbe; Michael C Kirchberger; Thomas Eigentler; Carola Berking; Anja Gesierich; Angela M Krackhardt; Dirk Schadendorf; Gerold Schuler; Reinhard Dummer; Lucie M Heinzerling
Journal:  Eur J Cancer       Date:  2016-04-13       Impact factor: 9.162

6.  Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

Authors:  Kimberly E Beck; Joseph A Blansfield; Khoi Q Tran; Andrew L Feldman; Marybeth S Hughes; Richard E Royal; Udai S Kammula; Suzanne L Topalian; Richard M Sherry; David Kleiner; Martha Quezado; Israel Lowy; Michael Yellin; Steven A Rosenberg; James C Yang
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

7.  Nano-cage-mediated refolding of insulin by PEG-PE micelle.

Authors:  Xiaocui Fang; Tao Yang; Luoyang Wang; Jibing Yu; Xiuli Wei; Yinjian Zhou; Chen Wang; Wei Liang
Journal:  Biomaterials       Date:  2015-11-10       Impact factor: 12.479

8.  PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.

Authors:  Christian Blank; Ian Brown; Amy C Peterson; Mike Spiotto; Yoshiko Iwai; Tasuku Honjo; Thomas F Gajewski
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

9.  High sensitivity of cancer exome-based CD8 T cell neo-antigen identification.

Authors:  Marit M van Buuren; Jorg Ja Calis; Ton Nm Schumacher
Journal:  Oncoimmunology       Date:  2014-05-14       Impact factor: 8.110

10.  A STING-activating nanovaccine for cancer immunotherapy.

Authors:  Min Luo; Hua Wang; Zhaohui Wang; Haocheng Cai; Zhigang Lu; Yang Li; Mingjian Du; Gang Huang; Chensu Wang; Xiang Chen; Matthew R Porembka; Jayanthi Lea; Arthur E Frankel; Yang-Xin Fu; Zhijian J Chen; Jinming Gao
Journal:  Nat Nanotechnol       Date:  2017-04-24       Impact factor: 39.213

View more
  4 in total

Review 1.  Nanoparticles as Physically- and Biochemically-Tuned Drug Formulations for Cancers Therapy.

Authors:  Valentina Foglizzo; Serena Marchiò
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

2.  STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation.

Authors:  Bo-Dou Zhang; Jun-Jun Wu; Wen-Hao Li; Hong-Guo Hu; Lang Zhao; Pei-Yang He; Yu-Fen Zhao; Yan-Mei Li
Journal:  Nano Res       Date:  2022-04-18       Impact factor: 10.269

Review 3.  Immunostimulatory Polymers as Adjuvants, Immunotherapies, and Delivery Systems.

Authors:  Adam M Weiss; Samir Hossainy; Stuart J Rowan; Jeffrey A Hubbell; Aaron P Esser-Kahn
Journal:  Macromolecules       Date:  2022-08-04       Impact factor: 6.057

Review 4.  Nanodelivery of STING agonists against cancer and infectious diseases.

Authors:  Jiarong Zhou; Christian J Ventura; Ronnie H Fang; Liangfang Zhang
Journal:  Mol Aspects Med       Date:  2021-08-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.